

August 17, 2023



**Current Price:** ₹ 4940.70

## STOCK DATA

BSE Code	532488
NSE Symbol	DIVISLAB
Reuters	DIVI.BO
Bloomberg	DIVI IN

## VALUE PARAMETERS

52 W H/L(Rs)	5362.00/3989.10
Mkt. Cap.(Rs Cr)	71039.69
Latest Equity(Subscribed)	71.89
Latest Reserve (cons.)	6117.70
Latest EPS (cons.) -Unit Curr.	46.50
Latest P/E Ratio -cons	106.25
Latest Bookvalue (cons.) -Unit Curr.	430.48
Latest P/BV - cons	11.48
Dividend Yield -%	0.30
Face Value	5.00

## SHARE HOLDING PATTERN (%)

Description as on	% of Holding 30/06/2023
Foreign	48.69
Institutions	17.02
Govt Holding	0.23
Non Promoter Corp. Hold.	0.32
Promoters	29.33
Public & Others	4.42

## Consolidated Financials Results

In Cr.

Particulars	Qtr Ending	Qtr Ending	Var. (%)
	Jun. 23	Jun. 22	
Total Income	4417.80	3795.60	16
OPM (%)	11.52	12.61	-109bps
OP	509.00	478.80	6
Other income	34.10	16.10	112
PBIDT	543.10	494.90	10
Net Finance Charges	106.20	92.70	15
PBDT	436.90	402.20	9
Depreciation	166.90	147.80	13
PBT	270.00	254.40	6
Tax expense	96.60	-69.50	-239
PAT	173.40	323.90	-46
Minority Interest	6.80	6.70	1
Profit after Minority Interest and Share of profit of Associates	166.60	317.20	-47
EPS (Rs)	11.59	22.06	

### Apollo Hospitals Q1FY24 Results: Sales up 16.39% but NP down 47%, below Estimates

Revenue from operations stood at Rs 4,417.8 crore during the quarter, up 16.39% from Rs 3,795.6 crore recorded in the same period last fiscal. Profit before tax rose 6.13% year on year (YoY) to Rs 270 crore in the quarter ended 30 June 2023. PAT slumps 47% YoY to Rs 167 cr.

During the quarter, the company's revenue from Healthcare Services was Rs 2,310.7 crore (up 13.71% YoY) and revenue from Digital Health & Pharmacy Distribution was Rs 1,805.4 crore (up 22.05% YoY) and the revenue from Retail Health & Diagnostics stood at Rs 318.7 crore (up 8.77% YoY).

As on 30 June 2023, Apollo Hospitals had 7,798 operating beds across the network (excluding AHLL & managed beds), out of which 14 hospitals were new with 2,380 operating beds. The new hospitals have a utilization of over 60% and are expected to witness double digit growth in volumes and improvement in utilization and profitability going forward.

During Q1 FY24, Apollo Hospitals continued to demonstrate its long standing and unwavering commitment to providing the best healthcare to everyone. It continued to push boundaries of medical excellence and achieved several significant milestones, thus further cementing its four decades of clinical leadership in the industry.

Apollo successfully conducted its landmark 23,000th solid organ transplant making it the largest transplant program in the world. Apollo is also now the largest robotic surgery destination in India with over 10,000 successful robotic surgeries. It expanded its dedicated Robotic Colorectal Surgery Programme across six major cities: Chennai, Hyderabad, Bangalore, Delhi, Mumbai, and Vishakhapatnam with more in the pipeline.

Apollo's collective experience in robotic colorectal surgery alone surpassed an impressive milestone of 1,000 procedures. These and many other milestones are outcomes of Apollo's

relentless pursuit of medical excellence so it can provide the best care in the world to its patients.

Apollo continues to invest into the future expanding our digital footprint as well as its physical footprint with over 2000 new beds being added over the next 4 years. Apollo is also upgrading its existing infrastructure and as of June 30, 2023, it has a network of 7,798 operating beds across its facilities, with 14 new hospitals contributing 2,380 operating beds. These new facilities have already achieved a utilization rate of 60% and are well poised for further growth and profitability in the coming quarters.

Apollo also remains focused on addressing the rising challenge of NCDs the world is facing. It has launched myProHealth - an advanced version of ProHealth, its industry leading health management program. myProHealth is powered by a proprietary AI engine developed by Apollo and brings in the era individualisation in healthcare. The AI engine studies the 360 degree profile of the customer, mapping it with Apollo's 4 decades of healthcare data to provide every customer an individualised set of tests and scans made specifically for their health profile, risk factors and more. It then pairs them with a qualified healthcare mentor who works with them through the program to reduce their health risks.

## Management Comment

**Dr. Prathap C Reddy, Chairman, Apollo Hospitals Group said,** "As pioneers in healthcare, we have consistently pushed the boundaries of medical innovation and technology. Our state-of-the-art facilities, coupled with the expertise of our world-class medical professionals, enable us to offer cutting-edge treatments and personalized care to patients from all walks of life. At Apollo we firmly believe that the heart of any healthcare institution lies in its compassion and empathy. Therefore, , we have nurtured a culture that values every patient's emotions, fears, and hopes. We take the time to listen, understand, and tailor our treatments to suit individual needs, ensuring a truly patient-centric approach.

We have witnessed healthy growth and performance in the first quarter of the fiscal year 2024. Apollo Hospitals remains dedicated to advancing healthcare excellence, embracing innovation, and expanding our reach to provide quality medical services to even more communities. We are grateful to our dedicated team of healthcare professionals, whose relentless commitment to patient care has contributed significantly to these remarkable achievements.

The escalating global challenge of non-communicable diseases (NCDs), the silent killers, continues to put at risk the health of communities at large. We are determined to face this challenge head-on, bolstered by our commitment to technology-led healthcare. At Apollo, we have harnessed AI as a powerful ally to make it an integral part of our healthcare ecosystem. With tools like the AI CVD, AI-enabled Apollo ProHealth platform, the Apollo Clinical Intelligence Engine (Apollo CIE), AI-integrated radiology and diagnostics workflow, and the AI-powered smart in-patient room automation system, we are using AI across the healthcare spectrum including prediction, prevention, diagnosis and personalized management. This remarkable fusion of technology and human touch is helping us deliver our promise of 'touching lives'.

As we step into the next quarter, our focus remains steadfast – to augment our doctors' expertise and revolutionize the overall patient experience as we continue steering Apollo towards a future where healthcare is proactive, personalized, and accessible to all.

E-mail: [researchfeedback@smcindiaonline.com](mailto:researchfeedback@smcindiaonline.com)



**Corporate Office:**  
11/6B, Shanti Chamber,  
Pusa Road, New Delhi - 110005  
Tel: +91-11-30111000  
[www.smcindiaonline.com](http://www.smcindiaonline.com)

**Mumbai Office:**  
Lotus Corporate Park, A Wing 401/402,  
4th Floor, Graham Firth Steel Compound,  
Off Western Express Highway, Jay Coach Signal,  
Goreagon (East) Mumbai - 400063  
Tel: 91-22-67341600, Fax: 91-22-28805606

**Kolkata Office:**  
18, Rabindra Sarani,  
Poddar Court, Gate No.- 4, 5th Floor, Kolkata-700001  
Tel: 91-33-39847000, Fax: 91-33-39847004

Investments in securities market are subject to market risks, read all the related documents carefully before investing. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. The securities quoted are for illustration only and are not recommendatory. SMC is a SEBI registered Research Analyst having registration number INH100001849. CIN : L74899DL1994PLC063609.

SMC Global Securities Ltd. (hereinafter referred to as "SMC") is regulated by the Securities and Exchange Board of India ("SEBI") and is licensed to carry on the business of broking, depository services and related activities. SMC is a registered member of National Stock Exchange of India Limited, Bombay Stock Exchange Limited, MSEI (Metropolitan Stock Exchange of India Ltd) and M/s SMC Comtrade Ltd is a registered member of National Commodity and Derivative Exchange Limited and Multi Commodity Exchanges of India and other commodity exchanges in India. SMC is also registered as a Depository Participant with CDSL and NSDL. SMC's other associates are registered as Merchant Bankers, Portfolio Managers, NBFC with SEBI and Reserve Bank of India. It also has registration with AMFI as a Mutual Fund Distributor.

SMC is a SEBI registered Research Analyst having registration number INH100001849. SMC or its associates has not been debarred/ suspended by SEBI or any other regulatory authority for accessing /dealing in securities market. SMC or its associates or its Research Analyst or his relatives do not hold any financial interest in the subject company interest at the time of publication of this Report. SMC or its associates or its Research Analyst or his relatives do not hold any actual/beneficial ownership of more than 1% (one percent) in the subject company, at the end of the month immediately preceding the date of publication of this Report. SMC or its associates its Research Analyst or his relatives does not have any material conflict of interest at the time of publication of this Report.

SMC or its associates/analyst has not received any compensation from the subject company covered by the Research Analyst during the past twelve months. The subject company has not been a client of SMC during the past twelve months. SMC or its associates has not received any compensation or other benefits from the subject company covered by analyst or third party in connection with the present Research Report. The Research Analyst has not served as an officer, director or employee of the subject company covered by him/her and SMC has not been engaged in the market making activity for the subject company covered by the Research Analyst in this report.

The views expressed by the Research Analyst in this Report are based solely on information available publicly available/internal data/ other reliable sources believed to be true. SMC does not represent/ provide any warranty expressly or impliedly to the accuracy, contents or views expressed herein and investors are advised to independently evaluate the market conditions/risks involved before making any investment decision. The research analysts who have prepared this Report hereby certify that the views /opinions expressed in this Report are their personal independent views/opinions in respect of the subject company.

**Disclaimer:** This Research Report is for the personal information of the authorized recipient and doesn't construe to be any investment, legal or taxation advice to the investor. It is only for private circulation and use. The Research Report is based upon information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied upon as such. No action is solicited on the basis of the contents of this Research Report. The Research Report should not be reproduced or redistributed to any other person(s) in any form without prior written permission of the SMC. The contents of this material are general and are neither comprehensive nor inclusive. Neither SMC nor any of its affiliates, associates, representatives, directors or employees shall be responsible for any loss or damage that may arise to any person due to any action taken on the basis of this Research Report. It does not constitute personal recommendations or take into account the particular investment objectives, financial situations or needs of an individual client or a corporate/s or any entity/s. All investments involve risk and past performance doesn't guarantee future results. The value of, and income from investments may vary because of the changes in the macro and micro factors given at a certain period of time. The person should use his/her own judgment while taking investment decisions. Please note that SMC its affiliates, Research Analyst, officers, directors, and employees, including persons involved in the preparation or issuance of this Research Report: (a) from time to time, may have long or short positions in, and buy or sell the securities thereof, of the subject company(ies) mentioned here in; or (b) be engaged in any other transaction involving such securities and earn brokerage or other compensation or act as a market maker in the financial instruments of the subject company(ies) discussed herein or may perform or seek to perform investment banking services for such company(ies) or act as advisor or lender/borrower to such subject company(ies); or (c) may have any other potential conflict of interest with respect to any recommendation and related information and opinions. All disputes shall be subject to the exclusive jurisdiction of Delhi High court.